Status:
COMPLETED
Vaginal Isonicotinic Acid Hydrazide (INH) Administration Prior to T380A Intrauterine Device Insertion
Lead Sponsor:
Aswan University Hospital
Conditions:
IUCD Complication
Eligibility:
FEMALE
18-45 years
Phase:
PHASE4
Brief Summary
To investigate whether vaginal isonicotinic acid hydrazide administered before intrauterine device (IUD) insertion reduces failed insertions, insertion-related complications and pain in in Women Deliv...
Detailed Description
Women may experience pain and technical difficulties may be encountered when insertion of an intrauterine device is attempted through a narrow cervical canal. intrauterine device insertion- related co...
Eligibility Criteria
Inclusion
- Non-pregnant women
- Women that did not receive any analgesics or Dinoprostone in the 24 hours prior to insertion
- Women who delivered only by cesarean section
Exclusion
- Women with any uterine abnormalities as congenital anomalies, endometrial lesions, adenomyosis, fibroids.
- Those with a Category 3 or 4 conditions for intrauterine device insertion according to the WHO Medical Eligibility Criteria for contraceptive use
- Allergy to isonicotinic acid hydrazide .
- Women refuse to participate in the study
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2021
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT04499989
Start Date
September 1 2020
End Date
August 1 2021
Last Update
August 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aswan University Hospital
Aswān, Egypt, 81528